Notable selling pressure: Kahn Brothers cut PFE exposure by 21.7% (-0.73% portfolio impact) and a Zacks #4 Sell rating adds to outflow risk, even as some buy-side positioning targets a turnaround opportunity.

Full-year 2025 revenues fell 2% operationally, with Q4 down 1.1% despite beating estimates, as COVID-19 sales plunged. Non-COVID revenues showed improvement, while new launches and acquisitions—from obesity GLP-1 candidates to Cresemba—delivered strong trial data and milestone growth, underpinning expectations for double-digit expansion in 2026.

Medicare drug pilot programs and government pricing directives are pressing for deeper discounts, while the TrumpRx partnership and strategic licensing deals aim to navigate mounting price controls; looming patent expirations from 2026–2030 and waning COVID-product revenues heighten the push for FDA Priority Reviews, global rights acquisitions, and incubator partnerships to sustain supply-chain ceilings and offset exclusivity cliffs.

Investor sentiment remains cautious, framing Pfizer as undervalued relative to history yet burdened by fading COVID sales and looming generic headwinds. Analysts are divided between bullish $30-plus price targets calling it a low-cost buy and those assigning it a Zacks #5 strong-sell for short-term risk. The market is pricing in steady guidance but remains skeptical, awaiting 2026 clinical readouts, obesity pipeline progress and AI deployment to validate upside expectations.